Niagen Bioscience (NAGE) Deferred Taxes (2011 - 2026)

Niagen Bioscience's (NAGE) quarterly Deferred Taxes came in at $41000.0 in Q1 2026, up 356.25% on a QoQ basis from -$16000.0 in Q4 2018.

Niagen Bioscience (NAGE) Deferred Taxes (2011 - 2026) Analysis & Trends

Niagen Bioscience (NAGE) has 7 years of Deferred Taxes data on file, last reported at $41000.0 in Q1 2026.

On a quarterly basis, Deferred Taxes changed N/A year-over-year to $41000.0 in Q1 2026; TTM through Mar 2026 was $41000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $2000.0, down 98.89% from the prior year.
Deferred Taxes for Q1 2026 stood at $41000.0, up from -$16000.0 in the prior quarter.
Over the last five years, Deferred Taxes for NAGE reached as high as $41000.0 in Q1 2026 and fell as low as $41000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-65.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	96.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Niagen Bioscience	253.47 Mn	186.92 Mn	19.98 Mn	41,000.00

Download Data